F8 and hemophilia: When considering inhibitor risk in severe patients on prophylaxis with nonreplacement therapy who have only intermittent exposure to FVIII, the data on patients with nonsevere hemophilia could be considered as a model for the treatment-related risk factors of inhibitor development.